Interstitial lung disease in patients treated with Cyclin-Dependent Kinase 4/6 inhibitors: A systematic review and meta-analysis of randomized controlled trials

S, 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, Ca - Cancer J Clin, 71, 209, 10.3322/caac.21660 H, 1975 Kz, 2020, Breast Cancer Res Treat, 183, 479, 10.1007/s10549-020-05783-3 Ag, 2019, Breast cancer treatment: a review, JAMA, 321, 288, 10.1001/jama.2018.19323 https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/207103Orig1s012lbl.pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209935s013lbl.pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214200s000lbl.pdf. Rs, 2015, The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol, 16, 25, 10.1016/S1470-2045(14)71159-3 Rs, 2016, Palbociclib and letrozole in advanced breast cancer, N Engl J Med, 375, 1925, 10.1056/NEJMoa1607303 Nc, 2015, Palbociclib in hormone-receptor-positive advanced breast cancer, N Engl J Med, 373, 209, 10.1056/NEJMoa1505270 Dickler, 2017, MONARCH 1, A phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory hr+/HER2- metastatic breast cancer, Clin Cancer Res, 23, 5218, 10.1158/1078-0432.CCR-17-0754 Jr, 2017, Monarch 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy, J Clin Oncol, 35, 2875, 10.1200/JCO.2017.73.7585 Mp, 2017, Monarch 3: abemaciclib as initial therapy for advanced breast cancer, J Clin Oncol, 35, 3638, 10.1200/JCO.2017.75.6155 Gn, 2016, Ribociclib as first-line therapy for HR-positive, advanced breast cancer, N Engl J Med, 375, 1738, 10.1056/NEJMoa1609709 Dj, 2019, Overall survival with ribociclib plus fulvestrant in advanced breast cancer, N Engl J Med, 382, 514 Sa, 2019, Overall survival with ribociclib plus endocrine therapy in breast cancer, N Engl J Med, 381, 307, 10.1056/NEJMoa1903765 https://www.clinicaltrials.gov/ct2/show/NCT02499770?term=02499770&draw=2&rank=1. https://www.clinicaltrials.gov/ct2/show/NCT02514447?term=02514447&draw=1&rank=1. https://www.clinicaltrials.gov/ct2/show/NCT03041311?term=03041311&draw=2&rank=1. Boap, 2021, PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews, BMJ, 372, n160 EL, 2021, Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 22, 212, 10.1016/S1470-2045(20)30642-2 Srd, 2020, Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE), J Clin Oncol, 38 Sm, 2020, Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial, Lancet Oncol, 21, 763, 10.1016/S1470-2045(20)30112-1 Qy, 2020, MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study, Ther Adv Med Oncol, 12 https://www.clinicaltrials.gov/ct2/show/NCT01740427?term=01740427&draw=2&rank=1. https://www.clinicaltrials.gov/ct2/show/results/NCT02107703?term=02107703&draw=2&rank=1. https://www.clinicaltrials.gov/ct2/show/NCT02450539?term=02450539&draw=2&rank=1. https://www.clinicaltrials.gov/ct2/show/NCT02499120?term=02499120&draw=2&rank=1. https://www.clinicaltrials.gov/ct2/show/NCT02152631?term=02152631&draw=2&rank=1. S, 2018, CDK 4/6 inhibitors as single agent in advanced solid tumors, Front Oncol, 8, 608, 10.3389/fonc.2018.00608 F, 2020, Durable response to palbociclib and letrozole in ovarian cancer with CDKN2A loss, Cancer Biol Ther, 21, 197, 10.1080/15384047.2019.1685291 C, 2018, Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer, Gut, 67, 2142, 10.1136/gutjnl-2017-315144 M, 2010, Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts, Cancer Res, 70, 3228, 10.1158/0008-5472.CAN-09-4559 Wr, 2010, Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM, Proc Natl Acad Sci U S A, 107, 11501, 10.1073/pnas.1001613107 B, 2010, Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy, Nat Genet, 42, 715, 10.1038/ng.619 P, 2015, Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA, Oncotarget, 6, 40557, 10.18632/oncotarget.5829 M, 2016, Targeting cyclin-dependent kinases in synovial sarcoma: palbociclib as a potential treatment for synovial sarcoma patients, Ann Surg Oncol, 23, 2745, 10.1245/s10434-016-5341-x R, 2006, Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells, Mol Cancer Therapeut, 5, 1299, 10.1158/1535-7163.MCT-05-0383 Yx, 2014, Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo, Mol Cancer Therapeut, 13, 2184, 10.1158/1535-7163.MCT-14-0387 Je, 2017, CDK4/6 dual inhibitor abemaciclib demonstrates compelling preclinical activity against esophageal adenocarcinoma: a novel therapeutic option for a deadly disease, Oncotarget, 8, 100421, 10.18632/oncotarget.22244 T, 2018, Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer, Ther Adv Med Oncol, 10 R, 2021, Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment, Breast Cancer Res Treat, 186, 219, 10.1007/s10549-020-06001-w Raschi, 2021, Thromboembolic events with cyclin-dependent kinase 4/6 inhibitors in the FDA adverse event reporting system, Cancers (Basel), 13, 1758, 10.3390/cancers13081758 Lm, 2017, Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations, Oncologist, 22, 1039, 10.1634/theoncologist.2017-0142 R, 2020, CDK4/6 inhibitors in breast cancer treatment: potential interactions with drug, gene, and pathophysiological conditions, Int J Mol Sci, 21, 6350, 10.3390/ijms21176350 Ka, 2019, Can CDK4/6 inhibitors cause fatal lung injury?, Expert Rev Anticancer Ther, 19, 917, 10.1080/14737140.2019.1674651 K, 2018, Palbociclib enhances pulmonary fibrosis in patients undergoing thoracic radiation therapy: a case series and review of the literature, Int J Radiat Oncol Biol Phys, 102 O, 2019, Fatal palbociclib -related interstitial pneumonitis, Arch Clin Med Case Rep, 3, 162 M, 2021, CDK 4/6 inhibitor induced lung injury: a case report and review of literature, Ecanc Med Sci, 15, 1245 A, 2021, Ribociclib-induced pneumonitis: a case report, Breast Care (Basel), 16, 307, 10.1159/000507647 G, 2018, A single institution experience with palbociclib toxicity requiring dose modifications, Breast Cancer Res Treat, 168, 381, 10.1007/s10549-017-4606-9 https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. N, 2021 Qy, 2020, A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib, Pharmacol Res, 156, 104686, 10.1016/j.phrs.2020.104686 SL, 2017, HR+, HER2- advanced breast cancer and CDK4/6 inhibitors: mode of action, clinical activity, and safety profiles, Curr Cancer Drug Targets, 17, 637 Lm, 2014, Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine, Invest N Drugs, 32, 825, 10.1007/s10637-014-0120-7 G, 2020, Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor, Expet Opin Drug Saf, 19, 945, 10.1080/14740338.2020.1781814 M, 2009, Cell cycle, CDKs and cancer: a changing paradigm, Nat Rev Cancer, 9, 153, 10.1038/nrc2602 B, 2020, CDK4/6 inhibition enhances pulmonary inflammatory infiltration in bleomycin-induced lung fibrosis, Respir Res, 21, 167, 10.1186/s12931-020-01433-w S, 2019, Safety and tolerability of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in Oncology, Drug Saf, 42, 181, 10.1007/s40264-018-0772-x M, 2012, Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches, Respir Res, 13, 39, 10.1186/1465-9921-13-39